Healthgevity

Supplement

Oral peptides and cutting-edge nutraceuticals that enhance longevity and optimize healthspan

Services

Ignite your metabolism
Gut Health First
Daily Advantage
Prime Stem CELLS

About

Healthgevity

At Healthgevity, our mission is to revolutionize the way we approach health and longevity through the power of pioneering science. We are dedicated to unlocking the potential of orally bioavailable peptides, proteins, and other natural bioactives. Our meticulously designed products are aimed at enhancing longevity, optimizing healthspan, and elevating the overall quality of life for healthcare practitioners and their patients. We are committed to innovation and collaboration, partnering with leading doctors and scientific researchers to transform cutting-edge discoveries into advanced therapeutic nutraceuticals that deliver consistent outcomes.

Unlock exclusive discounts and offers from Healthgevity and other trusted partners with an SSRP Pro Membership.

Enroll Now

Resource

Healthgevity Introduces hydraCELL+™, Featuring Formulation IP Developed by the Seeds Foundation for Cellular Research

EVENT

Grand Rounds

December 4 - 5, 2026

Grand Rounds

Coming Soon

RESOURCES

Join us in breaking down the latest research live.

VIEW ALL

SSRP Institute Welcomes Promoitalia as New Trusted Partner

PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [November 5, 2026] — The SSRP Institute announces that Promoitalia has joined its Trusted Partner Network following nomination and completion of the SSRP’s internal review process. Promoitalia is an Italian aesthetic medicine company that develops professional technologies, methodologies, and consumable products for regenerative aesthetics and skin health. Its work combines professional […]

READ NEWS

PODCAST

Redox Revolution

Nov 3, 2026

Ep.84 – Pollution, Pediatrics, and Prevention: Protecting Children from Environmental Threats

In this episode of Redox Revolution, Dr. Seeds discusses the dangerous effects of pollutants – especially for children – and what we can do to protect our most vulnerable.

SSRP Membership

Brain & Cognition · Longevity & Healthspan

VIDEO

Cellular Medicine Mondays

Nov 2, 2026

Ep. 112 - Peptide Therapy Gets a Smarter Upgrade

Preview only

Dissecting Protocols – Episode 112

Peptide Therapy Gets a Smarter Upgrade

Dr. Seeds addresses the often-overlooked challenges of peptide purity, patient adherence, and administration. He also shares the journey behind the Redox Smart Pen, highlighting years of collaboration with scientists, physicians, and formulators to help raise the standard for peptide therapy and advance the future of cellular medicine.

Preview Only — Become a member for full access

Dr. Seeds and Medivive Announce the Redox Smart Pen: A Novel Technology for Precise Peptide Administration

BREAKING NEWS WILLOUGHBY, Ohio [October 29, 2026] — Dr. Seeds and Medivive announce the launch of the Redox Smart Pen, an innovative pre-filled autoinjector peptide delivery system designed to improve precision and consistency in physician-directed peptide protocols. Importantly, the Redox Smart Pen was developed through a proprietary methodology focused on uniform potency, accuracy of administration, […]

READ NEWS

SSRP Institute Welcomes PharmaNutra as New Trusted Partner

PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [October 22, 2026] — The SSRP Institute announces that PharmaNutra has joined its Trusted Partner Network following nomination and completion of the SSRP’s internal review process. Founded in Italy in 2003, PharmaNutra is a pharmaceutical and nutraceutical company focused on the research, development, and production of nutritional supplements and medical devices. […]

READ NEWS

ARTICLE

William Seeds, MD

Oct 8, 2026

EP2, Tissue-Resident Macrophages, and a New Mechanism of Organ Aging

William Seeds, MD Oct 8, 2026

EP2, Tissue-Resident Macrophages, and a New Mechanism of Organ Aging

Revisiting a Journal Club Article, “Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging.” Science. 2026 Why This Paper Matters Most of the senescence conversation over the past decade has centered on a familiar cast: senescent fibroblasts, endothelial cells, adipocytes, and the drugs designed to clear them. This paper, which I discuss in […]

READ ARTICLE

Healthgevity Introduces hydraCELL+™, Featuring Formulation IP Developed by the Seeds Foundation for Cellular Research

BREAKING NEWS INTERLAKEN, N.J., [October 2, 2026] — Healthgevity, a practitioner-focused precision longevity nutrition company, announced the launch of hydraCELL+™, a cellular hydration and muscle-support formula built on proprietary formulation IP developed through the Seeds Foundation for Cellular Research and licensed to Healthgevity. The formula reflects the cellular medicine approach advanced by William Seeds, MD, and […]

READ NEWS

ARTICLE

William Seeds, MD

Sep 23, 2026

The Future of Regenerative Medicine May Begin with a Hair Follicle

William Seeds, MD Sep 23, 2026

The Future of Regenerative Medicine May Begin with a Hair Follicle

Why a Plucked Hair Follicle May Matter to the Future of Regenerative Medicine In this article, I return to a study that I discussed in a July Journal Club post. The study, published in Cells in 2024, investigated whether cells obtained from plucked, cryopreserved human hair follicles could be reprogrammed into induced pluripotent stem cells […]

READ ARTICLE

Certification Certification

Level 3

15 hrs 43 min

Peptide Therapy Certification 2026

The SSRP Peptide Therapy Certification course gives clinicians, researchers, and other healthcare providers a working method for applying Cellular Medicine principles to patient care through clinical peptide therapy. Across 19 faculty-led lessons, Dr. William Seeds and SSRP faculty, including Siobhan...

19 Lessons

15 hrs 43 min

View Course

In Case You Missed it: FDA Approves Mounjaro (tirzepatide) for CVD

HEADLINE SCIENCE [Sept 14, 2026] – On August 28, 2026, the FDA expanded the indication for Mounjaro (tirzepatide), approving the dual GIP/GLP-1 receptor agonist to reduce the risk of major adverse cardiovascular events—including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—in adults with type 2 diabetes at high cardiovascular risk. The decision makes tirzepatide the […]

READ NEWS

Peptide Therapy Certification 2027

Four Seasons Resort Orlando at Walt Disney World, FL

COMING SOON

Peptide Therapy Certification 2027

COMING SOON

Healthgevity

Healthgevity

Healthgevity Introduces hydraCELL+™, Featuring Formulation IP Developed by the Seeds Foundation for Cellular Research

Upcoming Events

Grand Rounds

Join us in breaking down the latest research live.